X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
entrectinib (57) 57
index medicus (54) 54
oncology (37) 37
humans (33) 33
ros1 (22) 22
pan-trk (20) 20
acquired-resistance (19) 19
alk inhibitor (19) 19
animals (18) 18
cancer (17) 17
female (14) 14
crizotinib (13) 13
mutation (13) 13
pharmacology & pharmacy (13) 13
rearrangements (13) 13
tumors (13) 13
inhibitor entrectinib (12) 12
alk (11) 11
cell lung-cancer (11) 11
protein kinase inhibitors - pharmacology (11) 11
receptor, trka - genetics (11) 11
trk (11) 11
expression (10) 10
kinases (10) 10
lung cancer (10) 10
antitumor-activity (9) 9
cell line, tumor (9) 9
etv6-ntrk3 gene fusion (9) 9
fusion (9) 9
gene rearrangement (9) 9
neuroblastoma (9) 9
targeted therapy (9) 9
benzamides - pharmacology (8) 8
carcinoma (8) 8
clinical-response (8) 8
colorectal cancer (8) 8
identification (8) 8
indazoles - pharmacology (8) 8
metastasis (8) 8
pathology (8) 8
potent (8) 8
receptor protein-tyrosine kinases - antagonists & inhibitors (8) 8
receptor, trka - antagonists & inhibitors (8) 8
tyrosine (8) 8
article (7) 7
clinical trials (7) 7
lung-cancer (7) 7
mutations (7) 7
nerve growth-factor (7) 7
proteins (7) 7
receptor (7) 7
receptor, trkb - antagonists & inhibitors (7) 7
trka (7) 7
trkb (7) 7
analog secretory carcinoma (6) 6
anaplastic lymphoma kinase (6) 6
antineoplastic agents - therapeutic use (6) 6
biomarkers, tumor - genetics (6) 6
chemistry, medicinal (6) 6
chemotherapy (6) 6
gene fusion (6) 6
inhibitor (6) 6
male (6) 6
middle aged (6) 6
neoplasms - drug therapy (6) 6
non-small cell lung cancer (6) 6
ntrk fusion (6) 6
ntrk1 (6) 6
oncogene proteins, fusion - genetics (6) 6
protein kinase inhibitors - therapeutic use (6) 6
resistance (6) 6
solid tumors (6) 6
trkc (6) 6
advanced solid tumors (5) 5
cancer therapies (5) 5
discovery (5) 5
genes (5) 5
immunohistochemistry (5) 5
inhibitors (5) 5
kinase (5) 5
lung neoplasms - drug therapy (5) 5
lung neoplasms - genetics (5) 5
membrane glycoproteins - antagonists & inhibitors (5) 5
membrane glycoproteins - genetics (5) 5
mice (5) 5
mice, nude (5) 5
neoplasms - genetics (5) 5
next-generation sequencing (5) 5
ntrk (5) 5
open-label (5) 5
oral pan-trk (5) 5
protein-tyrosine kinase (5) 5
receptor, trkc - antagonists & inhibitors (5) 5
tropomyosin (5) 5
tropomyosin receptor kinase (5) 5
adenocarcinoma (4) 4
adult (4) 4
aged (4) 4
antineoplastic agents - pharmacology (4) 4
benzamides - therapeutic use (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


CANCER DISCOVERY, ISSN 2159-8274, 10/2018, Volume 8, Issue 10, pp. 1227 - 1236
The use of tyrosine kinase inhibitors (TKI) with activity against ALK, ROS1, or TRKA-C can result in significant clinical benefit in patients with diverse... 
CELL LUNG-CANCER | ALK | KINASE INHIBITION | ENTRECTINIB | SOLID TUMORS | ONCOLOGY | OVERCOMES CRIZOTINIB RESISTANCE | ALECTINIB | ACQUIRED-RESISTANCE | TRK | ROS1
Journal Article
The Lancet Oncology, ISSN 1470-2045, 12/2019, Volume 20, Issue 12, pp. 1691 - 1701
Lorlatinib is a potent, brain-penetrant, third-generation tyrosine kinase inhibitor (TKI) that targets ALK and ROS1 with preclinical activity against most... 
ALK | ROS1 REARRANGEMENT | ENTRECTINIB | EFFICACY | ONCOLOGY | SAFETY | TARGETING ROS1 | ADENOCARCINOMA | CRIZOTINIB | MUTATIONS | INHIBITOR
Journal Article
Cancer Discovery, ISSN 2159-8274, 09/2017, Volume 7, Issue 9, pp. 934 - 936
Drug development for rare molecular targets in oncology presents unique challenges. In this issue of Cancer Discovery, Drilon and colleagues report the... 
ACQUIRED-RESISTANCE | TRIALS | MUTATIONS | ONCOLOGY | CANCER | INHIBITOR ENTRECTINIB
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 33, pp. 55353 - 55360
In colorectal cancer patients, chromosomal rearrangements involving NTRK1 gene (encoding the TRKA protein) are shown in a small subset of patients and are... 
NTRK1 | Entrectinib | TRKA | CRC | Rearrangement | PAN-TRK | entrectinib | KINASE | FUSIONS | ALK INHIBITOR | ROS1 | rearrangement | EGFR | CELL BIOLOGY
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2018, Volume 24, Issue 23, pp. 5807 - 5814
The oncogenesis-promoting role of chromosomal rearrangements for several hematologic and solid malignancies is well recognized. However, identifying... 
RECEPTOR TYROSINE KINASES | PAN-TRK | ONCOLOGY | ANALOG SECRETORY CARCINOMA | ETV6-NTRK3 GENE FUSION | INHIBITOR ENTRECTINIB | ACQUIRED-RESISTANCE | PAPILLARY THYROID-CARCINOMA | ANTITUMOR-ACTIVITY | REARRANGEMENTS | CLINICAL-RESPONSE
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 02/2018, Volume 61, Issue 4, pp. 1737 - 1743
Changes in expression and dysfunctional signaling of TrkA/B/C receptors and oncogenic Trk fusion proteins are found in neurological diseases and cancers. Here,... 
POTENT | ONCOGENE | CHEMISTRY, MEDICINAL | PAN-TRK | ENTRECTINIB | FUSION | RADIOFLUORINATION | ALZHEIMERS-DISEASE | EXPRESSION | CANCER | SCAFFOLD | Pharmacology & Pharmacy
Journal Article
Journal Article
PHARMACOGENOMICS, ISSN 1462-2416, 08/2019, Volume 20, Issue 13, pp. 927 - 929
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 10/2018, Volume 13, Issue 10, pp. 1474 - 1482
gene fusions are a well-characterized class of oncogenic driver found in approximately 1% to 2% of NSCLC patients. ROS1-directed therapy in these patients is... 
lung cancer | FISH | molecular testing | next-generation sequencing | ROS1 | ALK | RET | SOLID TUMORS | ADENOCARCINOMAS | OPEN-LABEL | CELL LUNG-CANCER | GENE FUSIONS | THERAPY | ENTRECTINIB | ONCOLOGY | RESPIRATORY SYSTEM | INHIBITOR
Journal Article
CANCER RESEARCH, ISSN 0008-5472, 07/2019, Volume 79, Issue 13, pp. 3163 - 3168
Oncogenic fusions involving NTRK1, NTRK2, and NTRK3 with various partners are diagnostic of infantile fibrosarcoma and secretory carcinoma yet also occur in... 
PAN-TRK | ONCOLOGY | ANALOG SECRETORY CARCINOMA | ETV6-NTRK3 GENE FUSION | INHIBITOR ENTRECTINIB | ANCHORED MULTIPLEX | ACQUIRED-RESISTANCE | IDENTIFICATION | CLINICAL-RESPONSE | EXPRESSION | MOLECULAR ANALYSIS
Journal Article
Annals of Oncology, ISSN 0923-7534, 05/2016, Volume 27, Issue 5, pp. 920 - 926
Journal Article
Cancer Discovery, ISSN 2159-8274, 09/2017, Volume 7, Issue 9, pp. 963 - 972
Journal Article
CLINICA CHIMICA ACTA, ISSN 0009-8981, 10/2018, Volume 485, pp. 298 - 304
Entrectinib (ENC) is a potent orally available anaplastic lymphoma kinase (ALK) inhibitor. In 10 July 2017, biotechnology company (Ignyta) announced that... 
ELUCIDATION | Human plasma | Quantification | STABILITY | BRIGATINIB | KINASE | TRK | DISCOVERY | LC-MS/MS | POTENT | Rat liver microsomes | Metabolic degradation assessment | Entrectinib | MEDICAL LABORATORY TECHNOLOGY | ROS1
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2019, Volume 30, Issue 9, pp. 1417 - 1427
Abstract Background NTRK1, NTRK2 and NTRK3 fusions are present in a plethora of malignancies across different histologies. These fusions represent the most... 
NTRK1 | NTRK2 | PAN-TRK | next-generation sequencing | NTRK3 | INHIBITOR ENTRECTINIB | ACQUIRED-RESISTANCE | fluorescence in situ hybridisation | PROTEIN-TYROSINE KINASE | CANCER | MESOBLASTIC NEPHROMA | ONCOLOGY | ANALOG SECRETORY CARCINOMA | ETV6-NTRK3 GENE FUSION | immunohistochemistry | MUTATIONS | EXPRESSION
Journal Article
ANNALS OF ONCOLOGY, ISSN 0923-7534, 11/2019, Volume 30, Issue Suppl 8, pp. VIII16 - VIII22
Due to the efficacy of tropomyosin receptor kinase (TRK) inhibitor therapy and the recent Food and Drug Administration approval of larotrectinib, it is now... 
ancillary testing | PAN-TRK | NTRK fusions | next-generation sequencing | INHIBITOR ENTRECTINIB | ACQUIRED-RESISTANCE | POPULATIONS | IDENTIFICATION | TROPOMYOSIN | SCREEN | ONCOLOGY | ANALOG SECRETORY CARCINOMA | ETV6-NTRK3 GENE FUSION | tyrosine kinase inhibitor | CLINICAL-RESPONSE | Reviews
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.